
Ipamorelin is a synthetic peptide of five amino acids that makes the pituitary release growth hormone. It acts on the ghrelin receptor, the same target as MK-677 and GHRP-6, and was described in 1998 as the first “selective” growth hormone secretagogue because, in pigs, it raised GH without raising cortisol or prolactin. In people it has barely been studied: one pharmacokinetic study in healthy men and two Phase 2 trials for gut recovery after surgery, the published one of which found no benefit over placebo. It is not approved anywhere, and WADA bans it at all times.
This review also covers ipamorelin injections (merged from our older injection guide). For comparisons, see CJC-1295 vs ipamorelin and MK-677 vs ipamorelin.
What is ipamorelin?
Ipamorelin (ipamorelin acetate) is a pentapeptide growth hormone secretagogue. It was first described in 1998 and later tested in people for gut recovery after bowel surgery (postoperative ileus). It is not a SARM, a steroid or growth hormone itself: it triggers the body’s own GH release, which then raises IGF-1. It contains unnatural amino acids, which the FDA notes makes quality testing harder.
How does it work?
Ipamorelin binds the ghrelin (GHS) receptor in the pituitary and hypothalamus, causing a pulse of growth hormone. In the 1999 study in healthy men, every dose produced a single GH pulse that peaked about 40 minutes after the infusion and then faded. In pigs, even very high doses did not raise ACTH or cortisol, unlike GHRP-2 and GHRP-6, and did not change LH, FSH, prolactin or TSH. That selectivity is the reason it is popular, but it has not been confirmed in published human studies.
What the human studies show
| Study | People | What was given | Result |
|---|---|---|---|
| Pharmacokinetic study (1999) | 40 healthy men | Single IV infusion over 15 min, 5 dose levels | Half-life about 2 h; one GH pulse peaking at about 40 min at every dose |
| Phase 2 surgery trial (2014) | 114 adults after bowel resection | 0.03 mg/kg IV twice daily, up to 7 days | Time to first tolerated meal 25.3 vs 32.6 h on placebo, not significant; well tolerated |
| Second Phase 2 trial | 320 patients | IV | Finished in 2014; no results posted |
No human study has tested ipamorelin for muscle, fat loss, recovery, sleep, bone or aging. Most “benefits” lists online extrapolate from what growth hormone does, or from animal studies.
Ipamorelin benefits: what is and isn’t shown
| Claim | Evidence |
|---|---|
| Raises growth hormone | Shown in healthy men (single IV dose) |
| No cortisol or prolactin rise | Pigs only |
| Muscle growth or preventing muscle loss | Animal studies only (with CJC-1295 in mice on steroids, in a 2026 review) |
| Fat loss | Not studied in people |
| Bone strength | Animal studies only |
| Better sleep | Not studied |
| Faster gut recovery after surgery | Tested in a Phase 2 trial; no benefit over placebo |

Ipamorelin half-life
About 2 hours after a 15-minute IV infusion in healthy men (one study). The GH response it caused was shorter, peaking at about 40 minutes. We found no published human half-life after injection under the skin, which is how it is usually used. By comparison, CJC-1295 with DAC lasts days and MK-677 is taken by mouth; see the half-life chart on this page.
Ipamorelin injections

Ipamorelin is sold as a freeze-dried powder that is reconstituted and injected, usually under the skin. It is not active by mouth in any study we found. The human studies gave it intravenously, so subcutaneous use, the common route, has no published human safety data; the FDA notes it found no safety data for routes other than IV. Unopened vials and reconstituted solutions should be stored as the batch’s paperwork says, usually refrigerated after mixing.
Dosing
We do not give personal doses. The human studies used single IV doses of 4.21 to 140.45 nmol/kg in healthy men and 0.03 mg/kg IV twice daily after surgery. No study set a dose for muscle, fat loss or aging, and the microgram schedules seen online are not based on human trials.
Ipamorelin side effects
In the surgery trial, adverse events were about as common with ipamorelin as with placebo (87.5% vs 94.8% of patients had any event, as expected after bowel surgery). The FDA cites a published report of serious adverse events, including death, when ipamorelin was given intravenously for gut motility, and lists it in Category 2 (significant safety risks) for outsourcing facilities. It also flags possible immune reactions from impurities or aggregation. A modified version, Gly-ipamorelin, has been found in black-market products. Users commonly report injection-site redness, headache, flushing and lightheadedness; these have not been measured in trials of subcutaneous use.
Is ipamorelin legal?
It is not an approved drug: there is no approved product in the FDA or EMA databases. Since 29 September 2023, the FDA has listed it in Category 2, significant safety risks, for outsourcing facilities (503B); the nomination for pharmacy compounding (503A) was withdrawn. In Australia it is a Schedule 4 prescription-only medicine, and possession without authority is illegal.
Ipamorelin in sports
WADA names ipamorelin under S2.2.4 (growth hormone secretagogues), prohibited at all times, and it stays on the 2027 List. Anti-doping labs test urine for ipamorelin and its metabolites; one metabolite, ipamorelin (1-4) free acid, was still found after the parent drug was gone. See SARMs and WADA.
Where to buy ipamorelin

Peptide quality is the main practical risk: the FDA flags impurities and immune reactions, and modified copies have been found on the black market. Sarmguide’s pick is SwissChems, which sells ipamorelin as 2 mg vials and publishes independent test results per batch. Check the batch’s certificate of analysis; our lab tests guide explains what to look for.
Conclusion
Ipamorelin reliably triggers a short growth hormone pulse, and in pigs it did so without raising cortisol. Everything beyond that, including muscle, fat loss, sleep and recovery, is untested in people, and its one completed clinical trial found no benefit. It is not approved, the FDA lists it as a safety risk for outsourcing facilities, and it is banned in sport. Related: CJC-1295 review · tesamorelin guide · best growth hormone peptides
Charts
| Dose studied | Who took part | Duration | What the study found | Source |
|---|---|---|---|---|
| 4.21 to 140.45 nmol/kg by IV infusion over 15 minutes (5 dose levels) | 40 healthy men (8 per dose level) | single infusion | randomized dose-escalation Dose-proportional blood levels, half-life about 2 hours; one GH pulse peaking at 0.67 hours at every dose. | PubMed 1999 |
| 0.03 mg/kg IV twice daily | 114 adults after bowel resection surgery | up to 7 days | phase 2 RCT Time to first tolerated meal 25.3 vs 32.6 hours with placebo (not significant). Well tolerated. | PubMed 2014 |
Sources: the studies linked in the table.
Source: Sarmguide compound database; Ipamorelin value: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999).
Frequently asked questions
What is ipamorelin?
A GH-releasing peptideEvidence: Human data
A synthetic five-amino-acid peptide that acts on the ghrelin receptor and makes the pituitary release growth hormone. It was described in 1998 as the first selective growth hormone secretagogue.
What does ipamorelin do?
Triggers a short GH pulseEvidence: Human data
In healthy men, GH peaked about 40 minutes after an IV dose. Effects on muscle, fat, sleep or recovery have not been tested in people.
Has ipamorelin been tested in humans?
BarelyEvidence: Trial
A 1999 study in 40 healthy men, and a 2014 Phase 2 trial in 114 surgery patients that found no benefit over placebo. A second Phase 2 trial finished in 2014 without posted results.
What is the half-life of ipamorelin?
About 2 hours (IV)Evidence: Human data
About 2 hours after an IV infusion in healthy men, in one study. No human half-life after injection under the skin has been published.
Does ipamorelin raise cortisol?
Not in pigs; unknown in peopleEvidence: Animal
In pigs it did not raise ACTH or cortisol, unlike GHRP-2 and GHRP-6. This has not been confirmed in published human studies.
What are the side effects of ipamorelin?
Long-term safety unknownEvidence: Trial
In the surgery trial, adverse events were as common as on placebo, but the FDA cites a report of serious adverse events, including death, with IV use. Safety of injection under the skin is unknown.
Is ipamorelin FDA approved?
NoEvidence: Law
There is no approved product, and since September 2023 the FDA has listed it in Category 2 (significant safety risks) for outsourcing facilities.
Is ipamorelin banned in sport?
Yes, banned by WADAEvidence: Law
WADA names it under S2.2.4 as a growth hormone secretagogue, prohibited at all times. Urine tests can detect it and its metabolites.
Can you combine ipamorelin with CJC-1295?
Not studied in peopleEvidence: Animal
It is a common combination, but it has not been studied in people. A 2026 review cites one mouse study in which the pair improved muscle force after steroid-induced muscle loss.
What is the best time to take ipamorelin?
Never studiedEvidence: Limited
No study has tested timing. Bedtime use is popular because natural GH pulses happen during sleep, but that rationale has not been tested in a trial.
Sources
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
- Ipamorelin, the first selective growth hormone secretagogue
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- Analysis of new growth promoting black market products
- Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 list; content current as of 22 Apr 2026)
- Therapeutic Goods (Poisons Standard - June 2026) Instrument 2026, F2026L00633 (Australia)
- World Anti-Doping Code International Standard: Prohibited List 2026